Is promethazine (Phenergan) safe to use during the first trimester of pregnancy?

Promethazine (Phenergan) Use in First Trimester

Promethazine can be used during the first trimester of pregnancy when clinically indicated, as it has not been shown to increase the risk of congenital malformations, though it should be used with appropriate caution given its FDA Pregnancy Category C classification.

FDA Classification and Official Guidance

The FDA classifies promethazine as Pregnancy Category C 1. This means:

• Animal studies at high doses (25 mg/kg intraperitoneally) have shown fetal mortality in rats
• Lower doses (6.25-12.5 mg/kg) in rat feeding studies showed no teratogenic effects
• No adequate and well-controlled studies exist in pregnant women
• The drug should be used "only if the potential benefit justifies the potential risk to the fetus" 1

Clinical Evidence for Safety

Large Population Studies Show Reassurance

The most robust human data comes from a Hungarian population-based case-control study examining 22,843 cases with congenital abnormalities:

• 16.0% of cases (3,648) and 15.8% of controls (6,025) had promethazine exposure during pregnancy
• Initial analysis suggested possible associations with cleft lip/palate and polysyndactyly, but these were explained by recall bias
• When only medically-recorded promethazine use was evaluated, no increased risk of congenital abnormalities was confirmed 2

Prospective Observational Data

A prospective study of 550 live births found:

• 143 infants exposed to promethazine or ondansetron during pregnancy
• No clinically significant adverse neurobehavioral effects on Neonatal Behavioral Assessment Scale at 7 days
• No adverse effects on Child Behavior Checklist at 17-66 months
• Only minor differences in gestational age (0.3 weeks) and birthweight (110 g) that were statistically but not clinically significant 3

High-Dose Exposure Data

Even in extreme circumstances (suicide attempts with 125-1750 mg doses):

• 32 pregnant women who attempted suicide with promethazine delivered live births
• No teratogenic or fetotoxic effects were demonstrated when comparing exposed children to their unexposed siblings
• The rate of congenital abnormalities was not significantly different between exposed children and sibling controls 4

Current Clinical Practice Guidelines

Nausea and Vomiting in Pregnancy

The 2024 AGA Clinical Practice Update on pregnancy-related GI disease states:

• Promethazine is used for hyperemesis gravidarum (HG) treatment
• In a randomized study comparing promethazine to metoclopramide for hospitalized HG patients, both had similar efficacy
• A Cochrane meta-analysis of 25 studies found no significant difference in efficacy among metoclopramide, ondansetron, and promethazine 5

The guidelines recommend phenothiazines (which includes promethazine) as first-line pharmacologic treatment for hyperemesis gravidarum, alongside doxylamine and pyridoxine 5.

Antihistamine Use in Pregnancy

The 2008 rhinitis practice parameter notes:

• First-generation antihistamines like chlorpheniramine have been traditionally recommended due to their "observed safety and longevity of use"
• Both first-generation and second-generation antihistamines in general have excellent safety records and do not show significant increases in congenital malformations when used during the first trimester 6

However, the 2007 British urticaria guidelines recommend:

• "It is best to avoid all antihistamines in pregnancy, especially during the first trimester, although none has been shown to be teratogenic in humans"
• When antihistamine therapy is necessary, chlorphenamine is often chosen due to its long safety record 7

Important Caveats and Warnings

Specific Concerns to Monitor

1. Extrapyramidal effects: Phenothiazines (including promethazine) can cause drug-induced extrapyramidal symptoms. The drug should be withdrawn if patients report such symptoms 5

2. Near-term use: Promethazine administered within two weeks of delivery may inhibit platelet aggregation in the newborn 1

3. Comparison to other antihistamines: While promethazine appears safe, hydroxyzine should be used cautiously during the first trimester based on animal data and is specifically contraindicated in early pregnancy in UK labeling 6, 7, 6

Data Quality Limitations

Despite widespread use, promethazine has limited high-quality data:

• A 2013 study identified promethazine as one of the most commonly used prescription medications in the first trimester (among the top 6)
• However, it does not have "Good to Excellent" data available to assess teratogenic risk according to TERIS expert review 8
• A 2012 review noted that "none of the antihistamines available today have been categorized as safe during pregnancy" and that "every drug used in pregnancy carries a risk for teratogenicity" 9

Clinical Decision-Making Algorithm

When promethazine is being considered in the first trimester:

1. Assess indication severity: Is the nausea/vomiting causing dehydration, weight loss, or inability to maintain nutrition?

2. Try non-pharmacologic measures first: Dietary modifications, vitamin B6 supplementation

3. If medication needed:

   • For mild-moderate nausea: Consider doxylamine-pyridoxine combination first (this is specifically FDA-approved for pregnancy)
   • For moderate-severe nausea or hyperemesis: Promethazine is appropriate as first-line therapy based on current guidelines 5

4. Dosing considerations: Use the lowest effective dose for the shortest duration necessary

5. Avoid near delivery: Discontinue at least 2 weeks before expected delivery if possible to avoid neonatal platelet effects 1

6. Monitor for side effects: Watch for extrapyramidal symptoms, excessive sedation

Bottom Line

Promethazine has extensive real-world use data showing no increased risk of major congenital malformations when used in the first trimester, with the largest population-based study specifically refuting initial concerns about cleft palate and limb defects 2. Current gastroenterology guidelines recommend phenothiazines (including promethazine) as first-line treatment for hyperemesis gravidarum 5. While the FDA Category C classification reflects the lack of controlled human studies, the available observational evidence from thousands of exposures is reassuring. The benefit of treating severe nausea and vomiting to prevent maternal dehydration and malnutrition typically outweighs the theoretical risks, making promethazine a reasonable choice when clinically indicated during the first trimester.